An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Stopped early

Conditions studied: Hepatitis B, Hepatitis, Liver Diseases

In brief

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

Key facts

Study ID
NCT03692897
Run by
Target PharmaSolutions, Inc.
People needed
1708
Starts
2018-10-11
Expected to finish
2025-09-10
Last updated by the study team
2025-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.